Priveterra Acquisition Corp. (PMGM)
| Market Cap | 97.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 8.90M |
| EPS (ttm) | 0.21 |
| PE Ratio | 52.33 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 10.99 |
| Previous Close | 10.95 |
| Day's Range | 10.99 - 10.99 |
| 52-Week Range | 10.14 - 11.00 |
| Beta | 0.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About PMGM
Priveterra Acquisition Corp. II does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or business combination with one or more businesses. It intends to focus on companies in the restaurant, hospitality, and related technology and services sectors. The company was formerly known as Tastemaker Acquisition Corp. and changed its name to Priveterra Acquisition Corp. II in July 2023. Priveterra Acquisition Corp. II was incorporated in 2020 and is ba... [Read more]
News
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively.
Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra”), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President,...
Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra” and, after the consummation of its pending business combination (the “Business Combination”) and follo...
Priveterra Acquisition says it will list on NYSE after AEON combination
Priveterra Acquisition said that following its planned business combination with AEON Biopharma the combined company will list on the New York Stock Exchange.
Priveterra Acquisition Corp. Announces Intention to Transfer to NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Priveterra Acquisition Corp. (Nasdaq: PMGM) (“Priveterra” and, after the consummation of its pending business combination (the “Business Combination”) and follo...
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readout Financing represents minimum cash required to consummate th...
AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million
IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex...
AEON Biopharma and Priveterra Acquisition Corp. Announce Filing of S-4 Registration Statement for Proposed Business Combination
IRVINE, Calif.--(BUSINESS WIRE)--AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple deb...
AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine
– Topline data expected to be announced in 2H 2023 –
AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology
IRVINE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on the development of its proprietary botul...